Efficacy of Daflon 500 mg in Venous Leg Ulcer Healing: A Double-Blind,Randomized,Controlled Versus Placebo Trial in 107 Patients

Abstract

The objective of this study was to evaluate the efficacy of Daflon® 500 mg (Dios)* in venous ulcers. A multicenter, double-blind, randomized, controlled versus placebo (Plac) trial was conducted, with stratification according to the size of ulcer (≤ 10 cm and > 10 cm). The protocol called for a two-month treatment with Dios (one tablet = 450 mg micronized purified Diosmin) or a placebo, two tablets/day, in addition to compression therapy.

Evaluations were performed every fifteen days, from DO to D60. The primary endpoint, in accordance with Alexander House group requirements were: percentage of patients with complete ulcer healing, ie, comparison between Dios and Plac group at D60, and comparison of survival curves in each group between DO and D60 (log rank test). Secondary endpoints included ulcer surface area assessed by computerized plani metric measurements, qualitative evaluation of ulcers, and symptoms.

The patients were 105 men and women ranging in age from eighteen to eighty-five years, with standard compression stocking, who were undergoing standardized local care of ulcer and had no significant arterial disease (ankle/arm systolic pressure index > 0.8). Fifty-three patients received Dios, and 52 received Plac. The 2 groups were well matched for age (m ±1 SD = seventy-one ±eleven years), gender, ulcer size, and associated disorders.

Among patients with ulcer size ≤ 10 cm (Dios = 44, Plac = 47) a significantly larger number of patients had a complete ulcer healing at two months in the Dios group (n = 14) in comparison with the Plac group (n = 6) (32% vs 13%, P = 0.028) with a signifi cantly shorter time duration of healing (P = 0.037). No difference was shown for the secondary criteria, except for sensation of heavy legs (P = 0.039) and a less atonic aspect of ulcer (P = 0.030) in favor of Dios. Among the 14 patients with ulcer size > 10 cm (Dios = 9, Plac = 5), subjected to a descriptive analysis only, no ulcer healed.

This study showed that a two-month course of Daflon 500 mg at a daily dose of two tablets, in addition to conventional treatment, is of benefit in patients with venous ulcer ≤ 10 cm by accelerating complete healing.

Get full access to this article

View all access options for this article.

References

Jean-JacquesGuilhou, Pr.M.D., and Olivier Dereure , Dermatology-Phlebology Department, Hôpital Saint-Charles, Montpellier

Loïc Marzin, M.D. , Phlebology Department, Hôpital Notre Dame de Bon Secours, Paris

Pierre Ouvry, M.D. , Phlebology Clinic, Dieppe

François Zuccarelli, M.D. , Phlebology Department, Hôpital Saint-Michel, Paris

Clélia Debure, M.D. , Vascular Reeducation Department, Hôpital Broussais , Paris

Hervé Van Landuyt, M.D. , Dermatology Department, Hôpital Saint-Jacques, Besançon

Marie-Noëlle Gillet-Terver, M.D. , Dermatology Department, Hôpital Fournier, Nancy

Bernard Guillot, Pr.M.D. , Dermatology-Phlebology Department, Hôpital Carémeau , Nimes

Hervé Levesque, M.D. , Internal Medicine-Angiology Department, Hôpital Boisguillaume , Rouen

10.

Jean Mignot , Ph.D., Interface Laboratory, I.U.T. Besançon, Besançon

11.

Gérard Pillion, M.D. , International Research Institute Servier (I.R.I.S.), Courbevoie

12.

Benoit Février, M.D. , International Research Institute Servier (I.R.I.S.), Courbevoie

13.

Dominique Dubeaux, Pharm.D. , International Research Institute Servier (I.R.I.S.), Courbevoie

14.

Moffatt CJ , Franks PJ , Oldroyd M. , et al: An evaluation of community leg ulcer clinics. In: Phlebology 1992, ed. by Raymond-Martimbeau P , Prescott R , Zummo M. Paris: John Libbey Eurotext , 1992, pp 283-285.

15.

Gilly R. , Pillion G. , Frileux C. : Evaluation of a new vasoactive micronized flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: A double-blind, placebo controlled study. Phlebology 9:67-70, 1994.

16.

Ruckley CV : Treatment of venous ulceration. Compression therapy. Phlebology 1 (suppl) :22-26, 1992.

17.

Alexander House Group: Consensus paper on venous leg ulcers . Phlebology 7:48-58, 1992.

18.

Skene AI , Smith JM , Doré CJ , et al: Venous leg ulcers : A prognostic index to predict time to healing . Br Med J 305:1119-1121, 1992 .

19.

Coleridge-Smith PD , Thomas P. , et al: Causes of venous ulceration: A new hypothesis. Br Med J 296: 1726-1727, 1988 .

20.

Scurr JH , Coleridge-Smith PD : Pathogenesis of venous ulceration. Phlebology 1 (suppl) : :13-16, 1992.

21.

Whiston RJ , Hallet MB , Lane IF , et al: Lower limb neutrophil oxygen radical production is increased in venous hypertension. Phlebology 8:152-154, 1993.

22.

Friesenecker B. , Tsai AG , Allegra C. , et al: Oral administration of purified micronized flavonoid fraction suppresses leucocyte adhesion in ischemia-reperfusion injury: In vivo observations in the Hamster skin fold . Int J Microcirc 14:50-55, 1994.

23.

Bouskela E. , Donyo KA , Verbeuren TJ : Effects of Daflon 500 mg on increased microvascular permeability. Int J Microcirc 14 (suppl 1):79, 1994.

24.

Stucker O. , Bonhomme E. , Lenaers A. , et al: Daflon 500 mg depresses bradykinin-ischemia-induced microvascular leakage of FITC-Dextran in rat cremaster muscle. Int Angio 8 (suppl 4):39-43, 1989.

25.

Allegra C. , Bartolo MJ , Carioti B. , et al: An original hemorheological approach using intracapillary haematrocrit : Pharmacological effects on skin microcirculation exchanges. Int J Microcirc 14 (suppl 1):82, 1994.

26.

Layton AM , Ibbotson SH , Davies JA , et al: Randomized trial of oral aspirin for chronic venous leg ulcers . Lancet 344:165-166, 1994.

27.

Colgan MP , Dormandy JA , Jones PW , et al: Oxpentifylline treatment of venous ulcers of the leg. Br Med J 300:972-975, 1990.

28.

Rudofsky G. : Intravenous prostaglandin E1 in the treatment of venous ulcers—a double-blind, placebo-controlled trial. Vasa 28 (suppl):39-43, 1989.

29.

Layer GT , Stacey MC , Burnand KG : Stanozolol and the treatment of venous leg ulceration—an interim report . Phlebology 1:197-203, 1986.

30.

Belcaro G. , Marelli C. : Treatment of lipodermatosclerosis and ulceration in venous hypertension by elastic compression and fibrinolytic enhancement with defibrotide. Phlebology 4:91-106, 1989.

31.

Schultz-Ehrenburg U. , Muller B. : Two multicentre clinical trials of two different dosages of O-(β-Hydroxyethyl)-Rutosides in the treatment of leg ulcers . Phlebology 1 (suppl) :29-30, 1993.

32.

Leyh F. : Therapie des ulcus cruris venosum mit Maüsedornextrakt und Trimethylehesperidinchalkon . Therapiewoche 38:2325-2331, 1988 .

33.

Colgan MP , Moore DJ , Shanik DG : Drug therapy for venous ulcers: New methods of treatment. Phlebology 1 (suppl) :41-43, 1992.

34.

Burnand KG , Whimster I. , Naidoo A. , et al: Pericapillary fibrin in the ulcer-bearing skin of the leg: The cause of lipodermatosclerosis and venous ulceration. Br Med J 285:1071-1072, 1982.